Case Study: Collaboration Accelerates Potential ALS Treatment
October 19, 2018
One of the early Target ALS-supported consortia studying C9orf72 ALS put forward the idea that it may be possible to treat ALS by targeting C9orf72 peptides directly. To move this idea forward, Target ALS connected Neurimmune, a biotechnology company with a group of scientists with niche expertise in cellular and animal models of ALS. Target ALS then funded this new collaboration to accelerate the development of antibodies against C9orf72, which were tested in mouse models of the disease.
At the 2018 Annual Meeting of Target ALS, Neurimmune announced the development of a potential therapeutic option and discussed plans to launch a Phase I clinical trial on an accelerated schedule.
Related News
A New Generation of ALS Researchers
March 9, 2026
Honoring the Women Who Carry the ALS Journey
March 5, 2026
Jacqueline Stepp's Story
March 5, 2026
A New Clue to One of the Most Common Genetic Causes of ALS and FTD
February 28, 2026